Venture Road meets Diamyd Medical
By Greatland
During Venture Road Nordics, we spoke with Diamyd Medical about a major milestone: the world’s first Phase III trial in type 1 diabetes using a precision medicine approach . In this interview, CEO Ulf Hannelius shares what it means to be on the verge of entering the US market. Watch the full interview
During Venture Road Nordics, we sat down with Diamyd Medical for an in-depth interview conducted by Phosworks.
At the center of the conversation was a major milestone: “The first ever Phase III trial in the world in type 1 diabetes, with a precision medicine approach,” as described by Ulf Hannelius, CEO of Diamyd Medical.
The interview was featured as part of the Venture Road Nordics session “Seizing opportunity when going west: on the verge of entering the US market”, where Diamyd shared insights into their journey toward US expansion and what it takes to translate Nordic scientific excellence into global impact.
This conversation was especially meaningful in its continuity. We first met Diamyd —and Karin Rosen — in California last July. We met again in December, this time in the Nordics. Different geographies, same strategic focus: entering the US market.
A powerful example of how Venture Road connects ecosystems over time, not just across borders.
Watch the full interview below: